Search company, investor...
Allay Therapeutics company logo

Allay Therapeutics

allaytx.com

Founded Year

2016

Stage

Series C | Alive

Total Raised

$90.75M

Last Raised

$60M | 1 yr ago

About Allay Therapeutics

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. The company's proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available.

Headquarters Location

4040 Campbell Avenue Suite 110

Menlo Park, California, 94025,

United States

Missing: Allay Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Allay Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Allay Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Allay Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Allay Therapeutics Patents

Allay Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Amines
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/3/2020

12/21/2021

Dosage forms, Drug delivery devices, Amines, Analgesics, Phenols

Grant

Application Date

4/3/2020

Grant Date

12/21/2021

Title

Related Topics

Dosage forms, Drug delivery devices, Amines, Analgesics, Phenols

Status

Grant

Latest Allay Therapeutics News

Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market to Surpass US$ 6,127.5 Million by 2030, Says Coherent Market Insights (CMI)

Apr 19, 2022

therapeutics market is estimated to be valued at US$ 4,211.7 million in 2022 and expected to exhibit a CAGR of 4.8% over the forecast period (2022-2030). Key Trends and Analysis of the Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market: An increase in the number of knee surgeries and arthroplasty is expected to drive the market growth over the forecast period. For instance, according to data published by the Canadian Institute for Health Information in June 2021, more than 75,000 knee replacements were performed in Canada. Key players operating in the market are focusing on the development of novel therapeutics for the treatment of knee surgeries and arthroplasty pain management, which is expected to drive the market growth over the forecast period For instance, in May 2021, Allay Therapeutics, a pharmaceutical company   offers analgesic products for post-surgical pain management and recuperation made an announcement of the first ever clinical data which shows non-opioid pain relief. The data was validated from a Phase 1b/2a clinical study of Allay’s first candidate, ATX-101, in improvement to medicate pain after total knee arthroplasty surgery or total knee arthroplasty (replacement). ATX-101 is a small dissolvable product incorporating the approved local analgesic bupivacaine. Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4998 Key companies in the market are focusing on regulatory approvals, which is expected to drive the market growth over the forecast period For instance, in March 2020, GlaxoSmithKline plc, a science-led global healthcare company, announced the approval of Advil Dual Action with Acetaminophen by the U.S. Food and Drug Administration, as an over-the-counter (OTC) product for pain relief. Advil Dual Action gives relief for various symptoms and is the major formulation that merges acetaminophen and ibuprofen – two strong ingredients indicated for over-the-counter pain relief that work in different ways. Key Market Takeaways: The global knee surgeries and arthroplasty pain management therapeutics market is expected to exhibit a CAGR of 4.8% over the forecast period, owing to increasing research and development. In April 2021, Pfizer Inc., an American multinational biotechnology and pharmaceutical company, and Eli Lilly and Company, an American pharmaceutical company, announced top-line results from a Phase 3 study evaluating tanezumab 5 mg and 2.5 mg. The aim of the study was to correlate the 16-week efficacy of tanezumab and long-term joint safety relative to nonsteroidal anti-inflammatory drugs in patients with moderate-to-severe osteoarthritis of knee. The increasing number of arthroplasties is expected to drive the segment growth over the forecast period. For instance, according to an article published by RheumatologyAdvisor.com, that offers healthcare professionals a comprehensive knowledge base of practical rheumatology information and resources, in May 2019, researchers analyzed data from the U.S. National Inpatient Sample from 2000 to 2014 with Census Bureau data to develop projections for the use of total hip arthroplasty and total knee arthroplasty from 2020 to 2040. Based on their review of the data, researchers predicted that the annual number of total knee arthroplasty is predicted to increase by 56% in 2020 to 1,065,000 replacements; by 110% in 2025 to 1,272,000 replacements; by 182% in 2030 to 1,921,000 replacements; and by 401% in 2040 to 3,416,000 replacements in the U.S. North America is expected to exhibit a high growth rate in the global knee surgeries and arthroplasty pain management therapeutics market during the forecast period, owing to the increasing awareness about joint replacement surgery. For instance, in October 2020, Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, launched ‘Don't Let Pain Gain on You’, a multimedia campaign to inform and empower people who have delayed joint replacement surgery to have a conversation with their healthcare professional about confidently moving forward with their procedure. The campaign is informed by the results of a new U.S. survey that reveals nearly half (48%) of joint replacement surgery candidates have postponed treatment due to fears stemming from the COVID-19 pandemic. Competitive Landscape: Key players operating in the global knee surgeries and arthroplasty pain management therapeutics market include Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis  AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4998 Market Segmentation: Acetaminophen Hospital Pharmacies North America

Allay Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Allay Therapeutics Rank

Allay Therapeutics Frequently Asked Questions (FAQ)

  • When was Allay Therapeutics founded?

    Allay Therapeutics was founded in 2016.

  • Where is Allay Therapeutics's headquarters?

    Allay Therapeutics's headquarters is located at 4040 Campbell Avenue, Menlo Park.

  • What is Allay Therapeutics's latest funding round?

    Allay Therapeutics's latest funding round is Series C.

  • How much did Allay Therapeutics raise?

    Allay Therapeutics raised a total of $90.75M.

  • Who are the investors of Allay Therapeutics?

    Investors of Allay Therapeutics include New Enterprise Associates, WTT Investment, Arboretum Ventures, Brandon Capital, Temasek and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.